We are building a synergistic, multi-asset pipeline of next-generation gene therapy candidates that offer new approaches to gene replacement, knockdown, and delivery. This allows us to target a range of diseases for communities with few or no therapeutics today.
Our lead candidates based on AAv gene knockout via RNAi precision approach to silencing target genes. Our lead candidates are in preclinical phase targeting various rare debilitating neuromuscular diseases.
Website: https://armatusbio.com/